Alamar's IPO and the Proteomics Turn
From reading the blueprint to watching biology happen
Alamar's IPO is a signal that proteomics is becoming investable again — and that precision medicine is expanding beyond DNA. For the last two decades, the revolution was mostly genomic. Sequencing became cheaper, faster, more scalable, and clinically embedded. Entire markets were built on top of that infrastructure: tumor profiling, NIPT, MRD, rare disease testing, hereditary cancer, and now early cancer detection. Genomics gave us the blueprint.
But the blueprint is not the building. DNA is relatively digital: four letters, stable molecules, scalable readouts. Not simple — chromatin, methylation, regulation, and structural variation all matter — but still relatively orderly. Proteins are different. They fold, bind, degrade, modify, localize, aggregate, and interact in living systems. They are biology's factory floor: dynamic, contextual, noisy, and occasionally behaving like they were designed by a committee who had too many drinks!
That is why proteomics has always been both so promising and so frustrating. The stronger thesis is not that proteomics "replaces" genomics. It does not, because #NGSisUnstoppable, as well documented! The more strategic point is that genomics tells us what could happen; proteomics helps tell us what is happening. That distinction matters in drug development, patient stratification, pharmacodynamic monitoring, neurodegeneration, immunology, oncology, and eventually diagnostics.
This is where Alamar becomes interesting. Its NULISA chemistry and Argo HT platform are aimed at a specific bottleneck: high-sensitivity, automated, mid-plex protein measurement. Dan Brennan at TD Cowen frames Alamar as sitting in the gap between high-plex discovery platforms and low-plex translational or clinical tools, with NULISA offering femtomolar-to-attomolar sensitivity, flexible multiplexing, and automation. That "mid-plex" wedge matters. The proteomics market is not one market. It is a set of trade-offs: breadth versus sensitivity, discovery versus validation, mass spec versus affinity, high-plex versus low-plex, science project versus workflow. Alamar's pitch is not "we measure everything." It is closer to: we can measure the proteins that matter with enough sensitivity and reproducibility to move from interesting biology toward actionable biology.
The risk is analyzing Alamar in a vacuum. The future will likely be won by how protein data gets folded into multi-omic systems.
In oncology, DNA may tell us the mutation. RNA may tell us what is expressed. Methylation may reveal cell state or tissue context (including tissue of origin). Proteins may show pathway activation, immune signaling, resistance, toxicity, or drug response. In rare disease, WGS may identify the variant; proteomics may help show whether the downstream biology is actually disrupted. In neurology, ultrasensitive blood-based protein markers could help move the field from slow, symptom-led assessment to something more measurable and longitudinal.
That is the real opportunity: proteomics as a missing layer in the precision medicine operating system.
Alamar also has the classic tools model investors understand: instrument placements, consumables pull-through, menu expansion, and utilization. Cowen forecasts revenue growing from $74M in 2025 to $400M+ by 2030, with consumables becoming the dominant revenue driver over time. Of course, initiation reports are not tablets from Mount Sinai, but the architecture is clear: the box matters, the menu matters more, and the recurring workflow matters most. And we would agree with that!
That is the strategic read. In tools (like in diagnostics), the instrument is increasingly not the product. The workflow and insight is the product; the ability to connect biology to decisions is the product.
So my view on Alamar's IPO is simple: Proteomics is now entering its industrialization phase. It is harder, messier, more analogue, and more dependent on context, which is exactly why it may be so valuable.
If genomics taught us to read the script, proteomics may tell us whether the actors showed up, improvised, or quietly burned down the stage!